{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T05:15:49Z","timestamp":1788498949619,"version":"build-2803163510"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To develop and validate an interpretable machine learning model for predicting grade \u22653 chemotherapy-induced neutropenia (CIN) in patients with small cell lung cancer (SCLC), and to establish a web-based clinical decision support tool for individualized risk assessment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective observational analysis of prospectively collected clinical data and enrolled 209 patients with SCLC who underwent 840 chemotherapy cycles between 2019 and 2022 from Tianjin Medical University General Hospital. Patients rather than chemotherapy cycles were randomly assigned into the training (80%) and testing (20%) cohorts. Feature selection was performed using least absolute shrinkage and selection operator regression and the Boruta algorithm. Machine learning algorithms were compared using patient-level 5-fold GroupKFold cross-validation. Hyperparameters were optimized using Optuna, and model interpretability was evaluated using Shapley additive explanations, Local interpretable model-agnostic explanations, Partial dependence plots. Three clinically oriented probability thresholds were further assessed to support different clinical decision-making scenarios. A web-based clinical decision support tool was subsequently developed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      CatBoost achieved the highest cross-validation performance while demonstrating the most stable results across folds, and was selected as the final model. Five predictors were selected for model development, including chemotherapy cycle, chemotherapy regimen, prophylactic medication, absolute neutrophil count (ANC) and rescue treatment in the prior cycle. In the independent testing cohort, the optimized CatBoost model achieved an AUC of 0.785 (95% CI, 0.706\u20130.865), with good calibration and favorable clinical net benefit. Threshold-specific analyses illustrated the expected sensitivity\u2013specificity trade-offs for exploratory screening- and confirmatory-oriented operating points. Interpretability analyses identified early chemotherapy cycles, rescue treatment in the prior cycle, absence of prophylactic medication, VP16 plus platinum regimen, and lower baseline ANC as predictors associated with higher CIN risk in this dataset. The model was further deployed as an interactive web-based application, available at\n                      <jats:ext-link>http:\/\/39.96.172.15:8080\/<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>An interpretable CatBoost model was developed for predicting grade \u22653 CIN in patients with SCLC. The integration of the model with a web-based clinical decision support tool may facilitate individualized risk stratification.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1939436","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T04:25:47Z","timestamp":1788495947000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Development and validation of an interpretable machine learning model for predicting chemotherapy-induced neutropenia in small cell lung cancer: a web-based clinical decision support tool"],"prefix":"10.3389","volume":"16","author":[{"given":"Jingyue","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Tianjin Medical University General Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyu","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tianjin Medical University General Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tianjin Medical University General Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zhai","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tianjin Medical University General Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahui","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tianjin Medical University General Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaomiao","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tianjin Medical University General Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanxu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tianjin Medical University General Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shijiao","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tianjin Medical University General Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Tian","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Tianjin Medical University General Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linlin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tianjin Medical University General Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hengjie","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tianjin Medical University General Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-00235-0","article-title":"Small-cell lung cancer","volume":"7","author":"Rudin","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2021.0058","article-title":"Small cell lung cancer, version 2.2022, NCCN clinical practice guidelines in oncology","volume":"19","author":"Ganti","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21847","article-title":"Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients","volume":"106","author":"Kuderer","year":"2006","journal-title":"Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2013.0148","article-title":"Myeloid growth factors","volume":"11","author":"Crawford","year":"2013","journal-title":"J Natl Compr Canc Netw"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2010.04.031","article-title":"Trends in G-CSF use in 990 patients after EORTC and ASCO guidelines","volume":"46","author":"Falandry","year":"2010","journal-title":"Eur J Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-010-0821-1","article-title":"Development and validation of a prediction model for the risk of developing febrile neutropenia in the first cycle of chemotherapy among elderly patients with breast, lung, colorectal, and prostate cancer","volume":"19","author":"Hosmer","year":"2011","journal-title":"Support Care Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pky053","article-title":"Development and validation of a risk score for febrile neutropenia after chemotherapy in patients with cancer: The FENCE score","volume":"2","author":"Aagaard","year":"2018","journal-title":"JNCI Cancer Spectr"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32249","article-title":"Development and validation of a cycle-specific risk score for febrile neutropenia during chemotherapy cycles 2-6 in patients with solid cancers: The (CSR) FENCE score","volume":"146","author":"Aagaard","year":"2020","journal-title":"Int J Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/CCI.21.00046","article-title":"Prediction of neutropenic events in chemotherapy patients: A machine learning approach","volume":"5","author":"Wiberg","year":"2021","journal-title":"JCO Clin Cancer Inform"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.4465","article-title":"Improved risk prediction of chemotherapy-induced neutropenia-model development and validation with real-world data","volume":"11","author":"Ven\u00e4l\u00e4inen","year":"2022","journal-title":"Cancer Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2019.05.009","article-title":"Using the Common Terminology Criteria for Adverse Events (CTCAE - Version 5.0) to evaluate the severity of adverse events of anticancer therapies","volume":"112","author":"Freites-Martinez","year":"2021","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3978\/j.issn.2305-5839.2015.12.63","article-title":"Multiple imputation with multivariate imputation by chained equation (MICE) package","volume":"4","author":"Zhang","year":"2016","journal-title":"Ann Transl Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/(sici)1097-0258(19970228)16:4<385::aid-sim380>3.0.co;2-3","article-title":"The lasso method for variable selection in the Cox model","volume":"16","author":"Tibshirani","year":"1997","journal-title":"Stat Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v036.i11","article-title":"Feature selection with Boruta package","volume":"36","author":"Kursa","year":"2010","journal-title":"J Stat Software"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.31557\/APJCP.2022.23.10.3287","article-title":"Comparison of classification success rates of different machine learning algorithms in the diagnosis of breast cancer","volume":"23","author":"Ozcan","year":"2022","journal-title":"Asian Pac J Cancer Prev"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16223791","article-title":"A hybrid deep learning and machine learning approach with Mobile-EfficientNet and Grey Wolf Optimizer for lung and colon cancer histopathology classification","volume":"16","author":"Ochoa-Ornelas","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1145\/3292500.3330701","article-title":"Optuna: A next-generation hyperparameter optimization framework","author":"Akiba","year":"2019","journal-title":"Proceedings of the 25th ACM SIGKDD International Conference on Knowledge Discovery and Data Mining"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X06295361","article-title":"Decision curve analysis: a novel method for evaluating prediction models","volume":"26","author":"Vickers","year":"2006","journal-title":"Med Decis Making"},{"key":"B19","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s42256-019-0138-9","article-title":"From local explanations to global understanding with explainable AI for trees","volume":"2","author":"Lundberg","year":"2020","journal-title":"Nat Mach Intell"},{"key":"B20","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s13534-023-00291-x","article-title":"Feasibility of local interpretable model-agnostic explanations (LIME) algorithm as an effective and interpretable feature selection method: Comparative fNIRS study","volume":"13","author":"Jaeyoung","year":"2023","journal-title":"BioMed Eng Lett"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1109\/TVCG.2025.3545025","article-title":"PDPilot: Exploring partial dependence plots through ranking, filtering, and clustering","volume":"31","author":"Kerrigan","year":"2025","journal-title":"IEEE Trans Vis Comput Graph"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-023-03451-1","article-title":"Chemotherapy-induced neutropenia as a prognostic factor in patients with extensive-stage small cell lung cancer","volume":"79","author":"Miyagi","year":"2023","journal-title":"Eur J Clin Pharmacol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/ecc.12723","article-title":"Comparison of irinotecan\/platinum versus etoposide\/platinum chemotherapy for extensive-stage small cell lung cancer: A meta-analysis","volume":"26","author":"Han","year":"2017","journal-title":"Eur J Cancer Care (Engl)"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2013.12.006","article-title":"Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: A systematic review","volume":"90","author":"Lyman","year":"2014","journal-title":"Crit Rev Oncol Hematol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejca.2010.10.013","article-title":"2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours","volume":"47","author":"Aapro","year":"2011","journal-title":"Eur J Cancer"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-018-1358-4","article-title":"Influence of UGT1A1 polymorphism on etoposide plus platinum-induced neutropenia in Japanese patients with small-cell lung cancer","volume":"24","author":"Negoro","year":"2019","journal-title":"Int J Clin Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3332\/ecancer.2023.1618","article-title":"The occurrence and risk factors of chemotherapy-induced neutropenia in patients with breast cancer not receiving primary G-CSF prophylaxis","volume":"17","author":"Hutajulu","year":"2023","journal-title":"Ecancermedicalscience"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19820615)49:12<2455::aid-cncr2820491206>3.0.co;2-4","article-title":"Marrow neutrophil reserve after adjuvant chemotherapy for carcinoma of the breast","volume":"49","author":"Corder","year":"1982","journal-title":"Cancer"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13071706","article-title":"An interpretable machine learning model based on inflammatory-nutritional biomarkers for predicting metachronous liver metastases after colorectal cancer surgery","volume":"13","author":"Zhu","year":"2025","journal-title":"Biomedicines"},{"key":"B30","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s40537-020-00369-8","article-title":"CatBoost for big data: An interdisciplinary review","volume":"7","author":"Hancock","year":"2020","journal-title":"J Big Data"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.15384","article-title":"Opening the black box of AI-medicine","volume":"36","author":"Poon","year":"2021","journal-title":"J Gastroenterol Hepatol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1186\/s12902-022-01121-4","article-title":"Opening the black box: Interpretable machine learning for predictor finding of metabolic syndrome","volume":"22","author":"Zhang","year":"2022","journal-title":"BMC Endocr Disord"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-020-0221-y","article-title":"An overview of clinical decision support systems: Benefits, risks, and strategies for success","volume":"3","author":"Sutton","year":"2020","journal-title":"NPJ Digit Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1939436\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T04:25:49Z","timestamp":1788495949000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1939436\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,4]]},"references-count":33,"alternative-id":["10.3389\/fonc.2026.1939436"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1939436","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,4]]},"article-number":"1939436"}}